Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 17:16:01 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Lipum Q3 - Awaiting clinical results

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Lipum Q3 - Awaiting clinical results

2024-10-25 12:00:00

Redeye provides a research update following the Q3 report published by Lipum earlier today. We are encouraged to learn that the company has managed to restrain its OPEX and operate in a cost-effective manner following the last-patient-in in the ongoing phase I study. Now, all eyes are on the final study results set to be published in the beginning of 2025. We reiterate our valuation of Lipum with a base case of SEK15.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/